Unicycive Therapeutics, Inc.
UNCY
$0.64
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.92% | 26.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.15% | -15.54% | |||
| Operating Income | -48.15% | 15.54% | |||
| Income Before Tax | -425.51% | -141.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -425.51% | -141.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -425.51% | -141.56% | |||
| EBIT | -48.15% | 15.54% | |||
| EBITDA | -48.18% | 15.62% | |||
| EPS Basic | -341.65% | -157.41% | |||
| Normalized Basic EPS | -342.01% | -117.72% | |||
| EPS Diluted | -341.65% | 68.51% | |||
| Normalized Diluted EPS | -342.01% | -143.97% | |||
| Average Basic Shares Outstanding | 18.86% | 134.59% | |||
| Average Diluted Shares Outstanding | 18.86% | -5.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -1.00% | |||